← Eichor
Study identifier: NCT07245576 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis

Condition: Asthma · COPD  ·  Sponsor: AstraZeneca

PhaseN/A
Planned participants600
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Current diagnostic methods for asthma and chronic obstructive pulmonary disease mostly depend on pulmonary function tests, especially spirometry. While spirometry is a foundational tool, its diagnostic accuracy is often limited by the patient's ability to perform forceful breathing maneuvers, as well as technical and reproducibility challenges, and the need for proper equipment and training. These constraints can compromise effective diagnosis of asthma and COPD in primary care settings. Prompt and accurate diagnosis by primary care physicians is essential for better patient outcomes. Although variable airflow limitation often measured as a change in FEV1 after bronchodilator is a hallmark of asthma, inconsistencies in test quality and reversibility criteria create challenges in distinguishing asthma from COPD. These complexities highlight the need for alternative diagnostic tools beyond traditional spirometry. This observational study is designed to evaluate the diagnostic accuracy and technical feasibility of using oscillometry and FeNO testing in primary care for suspected asthma and COPD, compared to conventional specialist-based diagnostics. The study will be conducted across 6 countries in the MEA, Asia, and Latin America, with two hospital sites per country. Primary care physicians will be trained in oscillometry and FeNO testing using standardized protocols and tools such as the Ambulatory Lung Diagnosis System following GINA and GOLD guidelines. Eligible patients wi…

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center  ·  1-877-240-9479  ·  information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (12)

Research SiteBuenos Aires, ArgentinaRecruiting
Research SiteMedoza, ArgentinaRecruiting
Research SiteAlexandria, EgyptNot Yet Recruiting
Research SiteEl Waili, EgyptNot Yet Recruiting
Research SiteMonterrey, MexicoNot Yet Recruiting
Research SiteSantiago de Quer Taro, MexicoNot Yet Recruiting
Research SiteRiyadh, Saudi ArabiaNot Yet Recruiting
Research SiteTaichung, TaiwanNot Yet Recruiting
Research SiteTaoyuan City, TaiwanNot Yet Recruiting
Research SiteDubai, United Arab EmiratesNot Yet Recruiting
Research SiteHanoi, VietnamNot Yet Recruiting
Research SiteHo Chi Minh City, VietnamNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07245576